How Much Insulin Your Pancreas Still Makes Affects Your Blood Sugar Control

Not everyone with Type 1 diabetes loses all their insulin-producing beta cells at the same rate. Some people retain what's called 'residual function'—meaning their pancreas still makes some insulin, even after diagnosis. A new study published in Frontiers in Endocrinology explored whether this residual function actually makes a difference in how well people's blood sugar stays in range.

Understanding what affects blood sugar control is important because it helps us recognize why two people on similar insulin doses might have very different glucose patterns. This knowledge can inform treatment decisions and help set realistic expectations for glucose management.

Researchers studied 112 people with Type 1 diabetes (including 68 with classic Type 1 and 44 with LADA) who wore continuous glucose monitors for at least 7 days. They measured how much insulin people's pancreases were still producing using a test called fasting C-peptide, then compared that to their CGM data.

The results were clear: people with higher C-peptide levels—meaning more residual insulin production—had better glucose control metrics. Specifically, they spent more time in their target glucose range, less time above range, and had lower average blood glucose levels overall. These benefits held up even when researchers accounted for other factors that affect blood sugar, like disease duration and daily insulin requirements.

The study also found patterns in who retained more residual function. People with shorter disease duration and those requiring lower daily insulin doses tended to have higher C-peptide levels. This makes biological sense: if your beta cells are working harder, you need less injected insulin to control your blood sugar.

These findings suggest that even small amounts of residual insulin production can meaningfully improve glucose control in Type 1 diabetes. This underscores why some researchers believe preserving remaining beta cell function—through immunotherapies or other approaches—could be valuable for people newly diagnosed with Type 1 diabetes.

This research demonstrates a measurable link between how much insulin your pancreas still makes and how well your blood sugar stays in range on a CGM. While Type 1 diabetes is an autoimmune condition that destroys beta cells, the presence of residual function correlates with better glucose metrics.

If you have Type 1 diabetes, this study doesn't change how you manage your condition—everyone's treatment plan is individual and should be discussed with your healthcare team. But it does highlight why preserving whatever beta cell function remains, if possible, could be part of a comprehensive approach to diabetes care.

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.